
    
      Objective of this pivotal study was to assess the bioequivalence between Test Product:
      Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India and the
      corresponding Reference Product: SeroquelÂ® (Quetiapine fumarate) Tablets 25 mg of M/s
      AstraZeneca Pharmaceuticals LP, USA, under fasting condition in normal, healthy, adult, human
      subjects in a randomized crossover study.

      The study was conducted with 54 healthy adult subjects. In each study period, a single 25 mg
      dose of either test or reference was administered to the subjects as per the randomization
      schedule in each study period with about 240 mL of water at ambient temperature in sitting
      position.

      The duration of the clinical phase was approximately 11 days including washout period of at
      least 7 days between administrations of study drug in each study period.
    
  